Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT

Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT

Trial design: A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne®, Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarria...

Full description

Bibliographic Details
Main Authors: Adam Devall, Justin Chu, Leanne Beeson, Pollyanna Hardy, Versha Cheed, Yongzhong Sun, Tracy Roberts, Chidubem Okeke Ogwulu, Eleanor Williams, Laura Jones, Jenny La Fontaine Papadopoulos, Ruth Bender-Atik, Jane Brewin, Kim Hinshaw, Meenakshi Choudhary, Amna Ahmed, Joel Naftalin, Natalie Nunes, Abigail Oliver, Feras Izzat, Kalsang Bhatia, Ismail Hassan, Yadava Jeve, Judith Hamilton, Shilpa Deb, Cecilia Bottomley, Jackie Ross, Linda Watkins, Martyn Underwood, Ying Cheong, Chitra Kumar, Pratima Gupta, Rachel Small, Stewart Pringle, Frances Hodge, Anupama Shahid, Ioannis Gallos, Andrew Horne, Siobhan Quenby, Arri Coomarasamy
Format: Article
Language:English
Published: NIHR Journals Library 2021-11-01
Series:Health Technology Assessment
Subjects:
pregnancy
mifepristone
misoprostol
missed miscarriage
medical management
gestational sac
randomised controlled trial
Online Access:https://doi.org/10.3310/hta25680

Internet

https://doi.org/10.3310/hta25680

Similar Items